Endocrine Abstracts

Objectives: Screening of thyropathies in Slovakia began in 2009 on the basis of the expert guideline of the Ministry of Health of the Slovak Republic for the diagnosis and treatment of autoimmune thyroid diseases in women during pregnancy (Public Health Ministry 39, 2009, No. 33–39)

Methods: The records of pregnant women insured by the health insurance company Dôvera, who had their first documented gynecological visit due to pregnancy in 2011, while they had no records of an endocrinology visit in 2010. Women had blood taken for TSH and aTPO at the gynecologist and were subsequently examined by an endocrinologist, were involved in the study. An individual group that was monitored by an endocrinologist under diagnoses E.00 to E.07 by the end of 2013.

Results: Overall, 13,876 pregnant women insured by the health insurance company Dôvera, a.s. (27.50 market share) who have undergone the first examination in 2010 with confirmed pregnancy, were registered. Of this group 294 (2.19%) had a record of repeated endocrinology visit with dg. E.00 to E.07. 5,143 (37.06%) of 13,876 women women had blood taken for TSH (aTPO could not be identified), and 275 (5.35%) had at least two endocrinological examinations by the end of 2013. In 2011 207 (75.50%) women were prescribed at least 1 pack of thyroxin, in 2012 151 women (55.11%) and in 2012 195 women (70.80%). Of the thyreostatic drugs - thiamazole a prescription was documented only in two cases (0.70%) in 2013.The total cost for 2011-2013 was € 114,915. The cost of one case of the screening of trapped thrombotic pathology was € 399.50, the cost of one case of treated hypothyroidism was € 638.70. The cost for 1 case of hyperthyroidism was € 57,457.5.

Conclusions: The screening of thyroid pathology, evaluated in the 2 years of the MZ SR expert’s guide, show its low feasibility by gynecologist in the population of pregnant women - 37.06%. The prevalence of documented thyreopathies in pregnant women was found to be 2.19%, while the prevalence of newly diagnosed thyreopathies was 5.35%. The overall prevalence of thyropathy in the 30–35 year-old women category can be estimated at about 7.54%. From newly diagnosed thyreopathies was in the first year after the detection of thyreophaty therapy needed in 70%–76%. An identical study for the years 2016–2017 is planned to assess the state of the screening program after 5 years.